Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review

References

• Sun J, He WT, Wang L., et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26(5):483–495. doi:10.1016/j.molmed.2020.02.008
   PubMed Web of Science ®Google Scholar
• Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020;7(6):1012–1023. doi:10.1093/nsr/nwaa036
   PubMed Web of Science ®Google Scholar
• 3 Impfstoffe aus China drängen auf weltweiten Einsatz [homepage on the Internet]. Available from: https://www.aerzteblatt.de/nachrichten/120839/3-Impfstoffe-aus-China-draengen-auf-weltweiten-Einsatz. Accessed July 24, 2022.
   Google Scholar
• COVID 19 tracker [homepage on the internet]. McGill COVID19 Vaccine Tracker Team: COVID-19 Vaccine Tracker. McGill University. Available from: https://covid19.trackvaccines.org/. Accessed July 24, 2022.
   Google Scholar
• Which Covid-19 Vaccines Are Most Widely Used? [homepage on the internet]. Available from: https://www.statista.com/chart/24191/number-of-countries-using-selected-covid-19-vaccines/. Accessed July 24, 2022.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572–577. doi:10.1038/s41586-021-03653-6
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891. doi:10.1016/S0140-6736(21)00432-3
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, Phase 2/3 trial. Lancet. 2021;396(10267):1979–1993. doi:10.1016/S0140-6736(20)32466-1
   PubMed Web of Science ®Google Scholar
• Loughlin AM, Marchant CD, Adams W, et al. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012;30(50):7253–7259. doi:10.1016/j.vaccine.2012.09.074
   PubMed Web of Science ®Google Scholar
• Saito K, Shimizu T, Suzuki-Inoue K, Ishida T, Wada Y. Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine. Neurol Sci. 2021;42(11):4433–4435. doi:10.1007/s10072-021-05543-1
   PubMed Web of Science ®Google Scholar
• Chan AC, Tan BY, Goh Y, Tan SS, Tambyah PA. Aseptic meningitis after BNT-162b2 COVID-19 vaccination. Brain Behav Immun Health. 2022;19:100406. doi:10.1016/j.bbih.2021.100406
   Google Scholar
• Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute Transverse Myelitis (ATM): clinicalReview of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021;12:653786. doi:10.3389/fimmu.2021.653786
   PubMed Web of Science ®Google Scholar
• Waheed W, Carey ME, Tandan SR, Tandan R. Post COVID-19 vaccine small fiber neuropathy. Muscle Nerve. 2021;64(1):E1–E2. doi:10.1002/mus.27251
   Web of Science ®Google Scholar
• Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol. 2021;85(5):1274–1284. doi:10.1016/j.jaad.2021.07.054
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. [homepage on the internet]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed July 24, 2022.
   Google Scholar
• Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine. 2021;39:101061. doi:10.1016/j.eclinm.2021.101061
   PubMedGoogle Scholar
• European Medicines Agency. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots. Accessed July 24, 2022.
   Google Scholar
• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;384(22):2092–2101. doi:10.1056/NEJMoa2104840
   PubMed Web of Science ®Google Scholar
• Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(22):2124–2130. doi:10.1056/NEJMoa2104882
   PubMed Web of Science ®Google Scholar
• Tardy-Poncet B, Tardy B, Grelac F, et al. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol. 1994;45(3):252–257. doi:10.1002/ajh.2830450312
   Web of Science ®Google Scholar
• Rosenthal MA, Rischin D, McArthur G, et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol. 2002;13(5):770–776. doi:10.1093/annonc/mdf117
   PubMed Web of Science ®Google Scholar
• Moores G, Warkentin TE, Farooqi MAM, Jevtic SD, Zeller MP, Perera KS. Spontaneous Heparin-Induced Thrombocytopenia Presenting as Cerebral Venous Sinus Thrombosis. Neurol Clin Pract. 2021;11(6):e929–e931. doi:10.1212/CPJ.0000000000000805
   Google Scholar
• Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med. 2008;121(7):632–636. doi:10.1016/j.amjmed.2008.03.012
   PubMed Web of Science ®Google Scholar
• Denard J, Rouillon J, Leger T, et al. AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6. Mol Ther Methods Clin Dev. 2018;10:291–302. doi:10.1016/j.omtm.2018.08.001
   Web of Science ®Google Scholar
• Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost. 2021;19(7):1771–1775. doi:10.1111/jth.15347
   PubMed Web of Science ®Google Scholar
• Corrêa DG, Cañete LAQ, Dos Santos GAC, de Oliveira RV, Brandão CO. Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: cause or coincidence? Clin Imaging. 2021;80:348–352. doi:10.1016/j.clinimag.2021.08.021
   Web of Science ®Google Scholar
• Al-Mayhani T, Saber S, Stubbs MJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry. 2021;92(11):1247–1248. doi:10.1136/jnnp-2021-326984
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). 2022. Available from: www.training.cochrane.org/handbook. Accessed August 23, 2022.
   Google Scholar
• Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326(14):1390–1399. doi:10.1001/jama.2021.15072
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised Phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi:10.1016/S0140-6736(20)31866-3
   PubMed Web of Science ®Google Scholar
• Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. doi:10.1136/bmj.n1114
   PubMed Web of Science ®Google Scholar
• Whiteley WN, Ip S, Cooper JA, et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England. PLoS Med. 2022;19(2):e1003926. doi:10.1371/journal.pmed.1003926
   PubMed Web of Science ®Google Scholar
• Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data. J Autoimmun. 2021;122:102685. doi:10.1016/j.jaut.2021.102685
   PubMed Web of Science ®Google Scholar
• Cari L, Alhosseini MN, Fiore P, et al. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data. J Autoimmun. 2021;125:102742. doi:10.1016/j.jaut.2021.102742
   PubMed Web of Science ®Google Scholar
• Smadja DM, Yue QY, Chocron R, Sanchez O, Lillo-Le Louet A. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. 2021;58(1):2100956. doi:10.1183/13993003.00956-2021
   PubMed Web of Science ®Google Scholar
• Walter U, Fuchs M, Grossmann A, et al. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: a Case Report. Neurology. 2021;10:548. doi:10.1212/WNL.0000000000012576
   Web of Science ®Google Scholar
• Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet. 2021;397(10285):e11. doi:10.1016/S0140-6736(21
   PubMed Web of Science ®Google Scholar
• Costentin G, Ozkul-Wermester O, Triquenot A, et al. Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: impact on Recanalization Strategy. J Stroke Cerebrovasc Dis. 2021;30(9):105942. doi:10.1016/j.jstrokecerebrovasdis.2021.105942
   Web of Science ®Google Scholar
• Alammar MA. Ischemic stroke after AstraZeneca (Covid-19) vaccination. Saudi Med J. 2021;42(10):1136–1139. doi:10.15537/smj.2021.42.10.20210326
   Web of Science ®Google Scholar
• Bourguignon A, Arnold DM, Warkentin TE, et al. Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021;385(8):720–728. doi:10.1056/NEJMoa2107051
   Web of Science ®Google Scholar
• Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19. New England Journal of Medicine. 2021;384(23):2202–2211. doi:10.1056/NEJMoa2105385
   PubMed Web of Science ®Google Scholar
• Goereci Y, Kleineberg NN, Madlener M, et al. Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccination. Neurol Res Pract. 2021;3(1):52. doi:10.1186/s42466-021-00151-y
   Google Scholar
• Kenda J, Lovrič D, Škerget M, Milivojević N. Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2021;30(11):106072. doi:10.1016/j.jstrokecerebrovasdis.2021.106072
   PubMed Web of Science ®Google Scholar
• De Michele M, Iacobucci M, Chistolini A. Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nat Commun. 2021;12(1):4663. doi:10.1038/s41467-021-25010-x
   PubMed Web of Science ®Google Scholar
• Salih F, Schönborn L, Kohler S, et al. Vaccine-Induced Thrombocytopenia with Severe Headache. N Engl J Med. 2021;385(22):2103–2105. doi:10.1056/NEJMc2112974
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med. 2003;348(11):1067–1069. doi:10.1056/NEJM200303133481120
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286–1292. doi:10.1056/NEJM200104263441704
   PubMed Web of Science ®Google Scholar
• Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136(3):210–215. doi:10.7326/0003-4819-136-3-200202050-00009
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar